Unknown

Dataset Information

0

Generation of Orthotopic Patient-Derived Xenografts in Humanized Mice for Evaluation of Emerging Targeted Therapies and Immunotherapy Combinations for Melanoma.


ABSTRACT: Current methodologies for developing PDX in humanized mice in preclinical trials with immune-based therapies are limited by GVHD. Here, we compared two approaches for establishing PDX tumors in humanized mice: (1) PDX are first established in immune-deficient mice; or (2) PDX are initially established in humanized mice; then established PDX are transplanted to a larger cohort of humanized mice for preclinical trials. With the first approach, there was rapid wasting of PDX-bearing humanized mice with high levels of activated T cells in the circulation and organs, indicating immune-mediated toxicity. In contrast, with the second approach, toxicity was less of an issue and long-term human melanoma tumor growth and maintenance of human chimerism was achieved. Preclinical trials from the second approach revealed that rigosertib, but not anti-PD-1, increased CD8/CD4 T cell ratios in spleen and blood and inhibited PDX tumor growth. Resistance to anti-PD-1 was associated with PDX tumors established from tumors with limited CD8+ T cell content. Our findings suggest that it is essential to carefully manage immune editing by first establishing PDX tumors in humanized mice before expanding PDX tumors into a larger cohort of humanized mice to evaluate therapy response.

SUBMITTER: Yan C 

PROVIDER: S-EPMC10377652 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Generation of Orthotopic Patient-Derived Xenografts in Humanized Mice for Evaluation of Emerging Targeted Therapies and Immunotherapy Combinations for Melanoma.

Yan Chi C   Nebhan Caroline A CA   Saleh Nabil N   Shattuck-Brandt Rebecca R   Chen Sheau-Chiann SC   Ayers Gregory D GD   Weiss Vivian V   Richmond Ann A   Vilgelm Anna E AE  

Cancers 20230720 14


Current methodologies for developing PDX in humanized mice in preclinical trials with immune-based therapies are limited by GVHD. Here, we compared two approaches for establishing PDX tumors in humanized mice: (1) PDX are first established in immune-deficient mice; or (2) PDX are initially established in humanized mice; then established PDX are transplanted to a larger cohort of humanized mice for preclinical trials. With the first approach, there was rapid wasting of PDX-bearing humanized mice  ...[more]

Similar Datasets

| S-EPMC6061393 | biostudies-literature
| S-EPMC9302493 | biostudies-literature
| S-EPMC10113078 | biostudies-literature
| S-EPMC4494792 | biostudies-literature
| S-EPMC11860873 | biostudies-literature
| S-EPMC3929245 | biostudies-other
| S-EPMC5378732 | biostudies-literature
| S-EPMC7903462 | biostudies-literature
2017-12-31 | GSE80619 | GEO
| S-EPMC8582814 | biostudies-literature